{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T23:30:20Z","timestamp":1761262220332,"version":"build-2065373602"},"reference-count":54,"publisher":"Georg Thieme Verlag KG","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Klin Monbl Augenheilkd"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1055\/a-2563-4912","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T23:41:52Z","timestamp":1753314112000},"page":"1027-1041","source":"Crossref","is-referenced-by-count":0,"title":["Unerw\u00fcnschte okul\u00e4re Arzneimittelwirkungen von Chemotherapeutika"],"prefix":"10.1055","volume":"242","author":[{"given":"Louisa M","family":"Bulirsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin U.","family":"L\u00f6ffler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias Marten","family":"Mauschitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina C.","family":"Herwig-Carl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.4103\/IJO.IJO_2782_22","article-title":"A review on drug-induced dry eye disease","volume":"71","author":"KW Kam","year":"2023","journal-title":"Indian J Ophthalmol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2024.101302","article-title":"Ocular adverse events associated with antibody-drug conjugates used in cancer: Focus on pathophysiology and management strategies","volume":"103","author":"EE Gabison","year":"2024","journal-title":"Prog Retin Eye Res"},{"key":"ref3","first-page":"63","article-title":"Tissue factor expression in human pterygium","volume":"17","author":"R Ando","year":"2011","journal-title":"Mol Vis"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1177\/0192623312464311","article-title":"On-target and off-target-based toxicologic effects","volume":"41","author":"DG Rudmann","year":"2013","journal-title":"Toxicol Pathol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1073\/pnas.50.2.355","article-title":"A molecular mechanism of mitomycin action: linking of complementary DNA-strands","volume":"50","author":"VN Iyer","year":"1963","journal-title":"Proc Nat Acad Sci"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1038\/s41433-021-01422-3","article-title":"Ocular surface squamous neoplasia: management and outcomes","volume":"35","author":"R H\u00f6llhumer","year":"2021","journal-title":"Eye (Lond)"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1097\/ICU.0000000000000729","article-title":"History, presence, and future of mitomycin C in glaucoma filtration surgery","volume":"32","author":"JEJ Wolters","year":"2021","journal-title":"Curr Opin Ophthalmol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ophtha.2009.07.032","article-title":"Limbal Sstem cell deficiency after topical mitomycin C therapy for primary acquired melanosis with atypia","volume":"117","author":"A Lichtinger","year":"2010","journal-title":"Ophthalmology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ajo.2018.11.007","article-title":"Comparison of topical 5-fluorouracil and interferon alfa-2b as primary treatment modalities for ocular surface squamous neoplasia","volume":"199","author":"N Venkateswaran","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2147\/opth.s9709","article-title":"5-fluorouracil for the treatment of intraepithelial neoplasia and squamous cell carcinoma of the conjunctiva, and cornea","volume":"4","author":"A Al-Barrag","year":"2010","journal-title":"Clin Ophthalmol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1136\/bjophthalmol-2016-309219","article-title":"Topical 1% 5-fluoruracil as a sole treatment of corneoconjunctival ocular surface squamous neoplasia: Long-term study","volume":"101","author":"R Parrozzani","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0002-9394(14)74224-2","article-title":"Serious corneal complications of glaucoma filtering surgery with postoperative 5-fluorouracil","volume":"103","author":"A Knapp","year":"1987","journal-title":"Am J Ophthalmol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1055\/a-2029-0163","article-title":"Current practice in the treatment of epithelial and melanocytic tumours with interferon- \u03b1 2b: A survey of tertiary eye centres in Germany","volume":"240","author":"J Jiang","year":"2022","journal-title":"Klin Monbl Augenheilkd"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3109\/09273948.2010.486687","article-title":"Pegylated interferon alpha 2b for treatment of ocular surface squamousn: A pilot study","volume":"18","author":"CL Karp","year":"2010","journal-title":"Ocul Immunol Inflamm"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"81","DOI":"10.4103\/ojo.ojo_146_21","article-title":"Pegylated interferon-alpha-2a for the treatment of ocular surface squamous neoplasia","volume":"15","author":"M Nuruddin","year":"2022","journal-title":"Oman J Ophthalmol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/869604","article-title":"Update on intra-arterial chemotherapy for retinoblastoma","volume":"2014","author":"M Zanaty","year":"2014","journal-title":"ScientificWorldJournal"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/j.ophtha.2007.03.074","article-title":"Secondary acute myelogenous leukemia in patients with retinoblastoma: Is chemotherapy a factor?","volume":"114","author":"DS Gombos","year":"2007","journal-title":"Ophthalmology"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.696787","article-title":"Safety and efficacy of intravitreal chemotherapy (Melphalan) to treat vitreous seeds in retinoblastoma","volume":"12","author":"YA Yousef","year":"2021","journal-title":"Front Pharmacol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8628525","article-title":"Intravitreal melphalan chemotherapy for vitreous seeds in retinoblastoma","volume":"2020","author":"YA Yousef","year":"2020","journal-title":"J Ophthalmol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"305","DOI":"10.22336\/rjo.2023.49","article-title":"Toxicity to intravitreal melphalan in a patient with retinoblastoma","volume":"67","author":"MG Solaz-Ruiz","year":"2023","journal-title":"Rom J Ophthalmol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1001\/jamaophthalmol.2013.7666","article-title":"Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: Preliminary results","volume":"132","author":"CL Shields","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1001\/jamaophthalmol.2015.3119","article-title":"Anterior ocular toxicity of intravitreous melphalan for retinoblastoma","volume":"133","author":"JH Francis","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1001\/archophthalmol.2011.223","article-title":"Histopathologic observations after intra-arterial chemotherapy for retinoblastoma","volume":"129","author":"RC Eagle","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"657","DOI":"10.18502\/jovr.v16i4.9756","article-title":"Intravitreal methotrexate","volume":"16","author":"F Abdi","year":"2021","journal-title":"J Ophthalmic Vis Res"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1136\/bjo.2007.127928","article-title":"Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience","volume":"92","author":"S Frenkel","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.survophthal.2023.10.002","article-title":"Ocular surface toxicities associated with modern anticancer therapies","volume":"69","author":"R Boucher","year":"2024","journal-title":"Surv Ophthalmol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"S Lonial","year":"2020","journal-title":"Lancet Oncol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e801","DOI":"10.1016\/S2352-3026(23)00243-0","article-title":"Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study","volume":"10","author":"MA Dimopoulos","year":"2023","journal-title":"Lancet Haematol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.678634","article-title":"Ocular toxicity of belantamab mafodotin, an oncological perspective of management in relapsed and refractory multiple myeloma","volume":"11","author":"A Wahab","year":"2021","journal-title":"Front Oncol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","article-title":"Corneal epithelial findings in patients with multiple myeloma treated with antibody-drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study","volume":"9","author":"AV Farooq","year":"2020","journal-title":"Ophthalmol Ther"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"4629","DOI":"10.1158\/1078-0432.CCR-22-0618","article-title":"FDA approval summary: Belantamab mafodotin for patients with relapsed or refractory multiple myeloma","volume":"28","author":"AC Baines","year":"2022","journal-title":"Clin Cancer Res"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41408-024-01110-x","article-title":"Dynamics of microcyst-like epithelial changes associated with Belantamab mafodotin therapy in a patient with multiple myeloma\u2014a case report","volume":"14","author":"L Schloesser","year":"2024","journal-title":"Blood Cancer J"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/j.ophtha.2020.07.047","article-title":"Belantamab mafotodin-induced epithelial keratopathy masquerading myopic surgery","volume":"127","author":"A Rousseau","year":"2020","journal-title":"Ophthalmology"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1089\/jop.2024.0023","article-title":"Corneal Toxicity in Patients Treated by BELANTAMAB MAFODOTIN: How to Improve and Facilitate Patients Follow-Up Using Refractive Shift?","volume":"40","author":"J Chauvier","year":"2024","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1200\/JCO.22","article-title":"Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study","volume":"41","author":"UA Matulonis","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ajo.2022.06.009","article-title":"Corneal toxicity associated with belantamab mafodotin is not restricted to the epithelium: neuropathy studied with confocal microscopy","volume":"242","author":"J Aschauer","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2023.101979","article-title":"Acute keratoconjunctivitis associated with tisotumab vedotin-tftv for metastatic cervical cancer","volume":"33","author":"AA Parikh","year":"2024","journal-title":"Am J Ophthalmol Case Rep"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102867","article-title":"Practical clinical management of ocular adverse events related to Antibody-Drug Conjugates in gynaecological malignancies","volume":"134","author":"B Bouguerra Zina","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s00347-023-01852-2","article-title":"Ocular side effects of modern oncological therapy: Immunological checkpoint and MEK\/BRAF signal transduction inhibitors","volume":"120","author":"S Thurau","year":"2023","journal-title":"Ophthalmologie"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"e616","DOI":"10.1093\/oncolo\/oyae014","article-title":"Ocular Effects of MEK inhibitor therapy: Literature review, clinical presentation, and best practices for mitigation","volume":"29","author":"KW Jeng-Miller","year":"2024","journal-title":"Oncologist"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1007\/s00347-024-02101-w","article-title":"Panuveitis under dabrafenib\/trametinib treatment for malignant cutaneous melanoma persisting after completion of treatment","volume":"121","author":"M Sommer","year":"2024","journal-title":"Ophthalmologie"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002119","article-title":"Ocular adverse events in PD-1 and PD-L1 inhibitors","volume":"9","author":"L Young","year":"2021","journal-title":"J Immunother Cancer"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1038\/s41433-024-03212-z","article-title":"Impact of immune checkpoint inhibitors on vision and eye health","volume":"38","author":"M Masalkhi","year":"2024","journal-title":"Eye (Lond)"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1021713","article-title":"Immune-related keratitis is a rare complication associated with nivolumab treatment in a patient with advanced colorectal cancer: A case report","volume":"12","author":"Y Su","year":"2022","journal-title":"Front Oncol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.30638","article-title":"Myasthenia gravis in the setting of immune checkpoint inhibitor therapy: Practical considerations and opinion-based approach to acute management","volume":"14","author":"AS Zubair","year":"2022","journal-title":"Cureus"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1097\/IAE.0000000000002181","article-title":"Checkpoint inhibitor immune therapy: Systemic indications and ophthalmic side effects","volume":"38","author":"LA Dalvin","year":"2018","journal-title":"Retina"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ejca.2020.11.027","article-title":"The association between immune checkpoint or BRAF\/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma","volume":"144","author":"F Dimitriou","year":"2021","journal-title":"Eur J Cancer"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s00347-024-02114-5","article-title":"Bilateral choroidal detachment and hypotension under treatment with checkpoint inhibitors","volume":"121","author":"J Meinke","year":"2024","journal-title":"Ophthalmologie"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/09273948.2019.1577978","article-title":"Uveitis in patients treated with CTLA-4 and PD-1 checkpoint blockade inhibition","volume":"28","author":"MM Sun","year":"2020","journal-title":"Ocul Immunol Inflamm"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.survophthal.2023.02.003","article-title":"Tamoxifen retinopathy","volume":"68","author":"F Bazvand","year":"2023","journal-title":"Surv Ophthalmol"},{"key":"ref51","first-page":"315","article-title":"Tamoxifen retinopathy","volume":"62","author":"M Kaiser-Kupfer","year":"1978","journal-title":"Cancer Treat Rep"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.survophthal.2021.05.007","article-title":"Retinal toxicities of systemic anticancer drugs","volume":"67","author":"S Arora","year":"2022","journal-title":"Surv Ophthalmol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1046\/j.1442-9071.2004.00769.x","article-title":"Clinical case notes","volume":"32","author":"SM Colley","year":"2004","journal-title":"Clin Exp Ophthalmol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.survophthal.2023.07.003","article-title":"Tamoxifen retinopathy: A comprehensive review","volume":"69","author":"S Tenney","year":"2024","journal-title":"Surv Ophthalmol"}],"container-title":["Klinische Monatsbl\u00e4tter f\u00fcr Augenheilkunde"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2563-4912.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T23:23:54Z","timestamp":1761261834000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2563-4912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":54,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,15]]},"published-print":{"date-parts":[[2025,10]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2563-4912","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0023-2165","1439-3999"],"issn-type":[{"type":"print","value":"0023-2165"},{"type":"electronic","value":"1439-3999"}],"subject":[],"published":{"date-parts":[[2025,7,23]]}}}